Since April 2015
MD Medical Devices Consulting SAS provides specialist services to the Medical Devices Industry across Europe. Our international clients benefit from services in Senior Executive Search & Selection and Market Access. MD Medical Devices Consulting SAS consist of a team of Senior Consultants all who have had successful medical devices leadership experience with industry leaders globally or in Europe, being supported by an international back-up team in Paris.
Since January 2014
Enabling superior delivery precision and embolic protection in TAVI and other Cardiovascular Interventions through the patented SWAT™ technology
Since November 2013
Instant cardiac monitoring with a trigger to act decreasing time to appropriate tretament - a mHealth solution.
Since September 2012
Identify, assess and strategically decide on novel investment opportunities as well as portfolio companies to help creating new medical device Start-ups and supporting young Med Tech companies in developing and commercializing their innovative products, with the aim of improving patient treatment and increasing efficacy and efficiency in hospital care
Entrepreneur in Medical Devices and Life Science businesses
Since July 2011
Establishing, funding and strategic expansion of young Medical Device, Life Science or mHealth businesses, creation of new markets for and introduction of new innovative medical or mobile technologies, and establishing high specialist treatments in Interventional Medicine and Interventional Cardiology
Business Advisor Life Science
April 2013 --- January 2014
Business Advisors at Teknopol offers entrepreneurs coaching on how to build a business around a great idea and turn it into a scalable innovation.
Strategic expansion Arrhythmia Line
July 2011 --- February 2012
Assessing the market for and establishing new high specialist private arrhythmia clinics in Europe
Vice President AF Solutions
November 2010 --- December 2011
Promoted to spearhead comprehensive product development roadmap for a $55MM designer, manufacturer, and marketer of cardiology and cardiovascular robotic system used to treat arrhythmias and coronary artery disease in the U.S. and internationally. Lead global cross-functional team responsible for R&D, clinical affairs, marketing, and regulatory affairs. * Met aggressive proposal deadline for creating full product development roadmap that was presented and accepted by executive leadership team without changes. * Led team in creating roadmap that spanned beyond initial scope of 6-12 months to include 6-24 months. * Roadmap included company’s key products, robotic system, networked workstation, and information backbone solution for Interventional Cardiovascular labs. * Formulated roadmap based on voice of customer, OEM manufacturing partnerships, internal development capabilities, regulator pathways for U.S. and Europe, and available budget. * Devised entrepreneurial and new process for creating development roadmap. Took into account customer input, partners’ capabilities, costs, and timelines. * Model and process is now being applied to similar development projects in sister company.
General Manager EMEA
March 2008 --- December 2010
Full P&L accountability for EMEA business with combination of direct and distributor operations. Drove evidence-based selling and marketing activities to create new market space in EMEA for novel robotic technology in Interventional Cardiology. Managed 23-person team (capital sales, clinical adoption, administration, training, clinical engineering, technical service). * Grew total EMEA revenue 104% from US$10.3MM to US$21MM in 1 year. * Increased install base of robotic system 30% annually from 27 to 52 and utilization of robotic system 25% annually from 2700 to 4300 procedures. * Introduced robotic technology to new markets, including Sweden, Finland, and South Africa. * Increased global technical service revenues 56% by implementing outside U.S. business agreement with partner company. * Established 2 new global Reference Centers in Europe for capital site visits and clinical adoption training (both in use today by EMEA region and Asia Pacific Region). * Developed, expanded and aligned organizational capabilities to selling innovative and disruptive technologies based on processes and clinical evidence.
Vice President EMEA
September 2005 --- February 2008
Full P&L accountability for sales and marketing operations in direct countries of Europe – Germany, France, UK, Italy, and Benelux. Led direct field sales/marketing organization of 115 employees in direct (US$15MM in sales) and 85 employees in indirect sales (US$80MM) sales in EMEA. Oversaw marketing, clinical and regulatory affairs, technical service, and market development operations in EMEA headquarters in Waterloo, Belgium. * Ignited sales growth 30% year over year from 2005-2007. Expanded operations in East Europe via direct headcount resources and market subsidiaries. * Revamped sales strategies from product to procedure penetration based and implemented a novel Therapy Expansion marketing strategy across all countries and regions in EMEA via direct and/or indirect sales organization. * Established new sales and marketing division to manage introduction and distribution of new partner technology. * Optimized organizational structure while executing cost/headcount reduction of 9% to meet company’s income target.
January 2003 --- September 2005
Directed sales and marketing of Cordis and Biosense Webster cardiovascular products in Sweden, Denmark, Norway, Finland, and Baltic States. Led 4 areas of MSEK330MM cardiovascular business (Cordis Cardiology, Cordis Endovascular, Cordis Neurovascular, Biosense Webster) with full P&L accountability. Managed team of 25 through 6 direct reports. Member of Managing Board of Johnson & Johnson AB. Reported to CEO of Johnson & Johnson AB. * Doubled Cordis Cardiology Stent business to MSEK160MM in 2 years. * Created new market for new and innovative drug eluting stent technology for treatment of cardiac coronary vascular diseases. * Drove market preparation through financial reimbursement modeling in key markets and gaining support from European and Nordic key opinion leaders. Sold value of life transforming technology of drug eluting coronary stents through clinical data and evidence based selling. * Developed/implemented new sales model with premium pricing (200% above established stents) and created training program for employees and customers.
Director, Market Development, EMEA / Director, Clinical Development, EMEA
March 2001 --- January 2003
Drove 40%+ year over year growth reaching total of US$25MM in sales in East Europe countries, Russia, Middle East and Africa. Created national and regional growth strategies for the Biosense Webster business in collaboration with local J&J country management. Developed new novel e-learning based training series for external/internal customer in collaboration with training/marketing departments and worldwide key opinion leaders. Achieved CME accreditation in 2002.
Business Unit Manager, Nordic Region / Sales & Clinical Support Specialist
September 1997 --- March 2001
Drove 30% sales growth to SEK40MM via rapid penetration of novel technology for 3D mapping of heart rhythm disturbance. Managed 3 direct reports. As Sales Specialist, advanced sales of new 3-D diagnostic and therapeutic system for interventional electrophysiology and premium-priced disposable products. Increased penetration from 10% to 60% in 3 years covering 80% of major electrophysiology centers in Nordic region. Received Top 3 sales award in 1998 in Nordic Region.
Ph.D. in Clinical Electrophysiology from Lund University in 1997
M. Sc. in Biomedical Engineering from The Institute of Technology at Linköping University in 1987